Anzeige
❌
Mehr »
Login
Freitag, 02.05.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Met-Kohle-Margen, die selbst Branchengrößen blass aussehen lassen...
Anzeige

Indizes
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Aktien
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Xetra-Orderbuch

Fonds
Kurs
%

Devisen
Kurs
%

Rohstoffe
Kurs
%

Themen
Kurs
%

Erweiterte Suche

WKN: 853260 | ISIN: US4781601046 | Ticker-Symbol: JNJ
Tradegate
02.05.25
10:26 Uhr
137,58 Euro
-0,32
-0,23 %
Branche
Konsumgüter
Aktienmarkt
DJ Industrial
S&P 100
S&P 500
1-Jahres-Chart
JOHNSON & JOHNSON Chart 1 Jahr
5-Tage-Chart
JOHNSON & JOHNSON 5-Tage-Chart
RealtimeGeldBriefZeit
137,20137,3010:27
137,12137,5810:26

Aktuelle News zur JOHNSON & JOHNSON Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09:12J&J-backed HistoSonics explores sale at $2.5 billion valuation, FT reports2Seeking Alpha
DoFDA Nod for J&J Autoimmune Drug is First of Potentially Many for the Projected Blockbuster Product2MedCity News
DoReese Marketos LLP: Reese Marketos and Berger Montague Secure Historic $1.64 Billion False Claims Act Judgment Against Johnson & Johnson Subsidiary326ACCESS NewswireDALLAS, TEXAS / ACCESS Newswire / May 1, 2025 / In a landmark decision, law firms Reese Marketos and Berger Montague have secured a $1.64 billion judgment against Janssen Products, LP, a subsidiary...
► Artikel lesen
DoJ&J's IMAAVY Approved by FDA for Treatment of Generalized Myasthenia Gravis5Contract Pharma
DoGoldman Sachs updates conviction lists: Adds Johnson & Johnson and Axis Bank8Investing.com
DoFDA approves J&J's Imaavy for generalised myasthenia gravis5Pharmaceutical Technology
JOHNSON & JOHNSON Aktie jetzt für 0€ handeln
DoGoldman adds Houlihan Lokey, Johnson & Johnson to Conviction List6Investing.com
DoJ&J's 'Swiss army knife' drug gets first FDA approval1pharmaphorum
MiJohnson & Johnson (JNJ): Jim Cramer Says "They Love the Weak Dollar" - Is This Quiet Giant Back in Favor?2Insider Monkey
MiJOHNSON & JOHNSON - 8-K, Current Report3SEC Filings
MiJ&J secures FDA OK for immune drug touted as future blockbuster4BioPharma Dive
MiJ&J joins Argenx, UCB in the myasthenia gravis arena with FDA approval for FcRn blocker Imaavy13FiercePharma
MiJohnson & Johnson Announces FDA Approval Of IMAAVY260AFX NewsNEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced the FDA has approved IMAAVY, a human FcRn-blocking monoclonal antibody, for the treatment of generalized myasthenia gravis. The approval...
► Artikel lesen
MiJohnson & Johnson receives FDA approval for IMAAVY (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)81PR NewswireFirst and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older IMAAVY delivered rapid and...
► Artikel lesen
DiThree Cheap Stocks: Skechers, J&J, and P&G13Baystreet.ca
DiNvidia, JNJ, Toyota chiefs among White House guests for investment event- report16Investing.com
DiNvidia, Johnson & Johnson, Hyundai, Toyota, SoftBank CEOs To Join Trump At White House As He Touts Investment Surge In First 100 Days: Report22Benzinga.com
DiTrump to tout US investments from Nvidia, J&J, Hyundai, Toyota43Reuters
MoPlaintiff Sues Eli Lilly, Johnson & Johnson Over Alleged Breast Cancer Risk Linked To Antipsychotic Medications8Benzinga.com
MoJ&J's Tremfya gains EC marketing authorisation for ulcerative colitis3Pharmaceutical Technology
Seite:  1 2 3 4 5 Weiter >>
815 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
8,1,16